Home › Soft Tissue Sarcoma › NCT07402577
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
RecruitingObservational study
Who can join
Ages 12 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * All genders between the ages of 12-24 (inclusive) at sarcoma diagnosis. * Any age \< 70 at the time of study enrollment. * No evidence of disease and/or enrolled in survivorship care. * Clinically meaningful pain related to disease or its treatments at baseline (defined as 3 or greater on a 0-10 Numerical Rating Scale). * Willing to attend the baseline appointment in person. * Access to internet-capable smartphone. * Access to internet on an occasional basis. * Willing and able to complete Ecological Momentary Assessments (EMAs) on internet-capable smartphone for a 3-month period after enrollment. * Ability to understand and provide informed consent/assent. Exclusion Criteria: * \* Currently receiving active cancer-directed therapy. * Unable to read or fluently speak English. * Determined by clinical staff to have preexisting or cancer-associated cognitive impairment that could interfere with study participation. * Acutely suicidal (e.g. intent or plan) or, with unstable medical or psychiatric condition verified by licensed study staff. * Characteristics related to inability to complete the study protocol.
About the study
This study generates information on the feasibility and acceptability of a 3-month ecological momentary assessment (EMA) protocol to assess chronic pain and opioid use in adolescent and young adult (AYA) sarcoma survivors.
What is being tested
- Non Intervention Study (other)
Sponsor: Roswell Park Cancer Institute · Participants: 40 · Started: Mar 30, 2026
Contact the study team
- Andrew Rogers · Phone: 1-800-767-9355
Official record on ClinicalTrials.gov — NCT07402577
Locations in the U.S.
| New York | Roswell Park Comprehensive Cancer Center, Buffalo |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.